Facetheory

The premise was almost confrontational: that prestige skincare was charging a fortune for ingredients you could buy for a fraction of the price, and that someone with no industry pedigree could call the bluff. The founder arrived with no chemistry degree and no beauty-world connections, just a belief that shoppers were overpaying and a willingness to compete on substance instead of gloss.

The early proposition was deliberately unglamorous: clearly stated active concentrations, recyclable glass and aluminium packaging, formulas free of silicones and microplastics, and almost no traditional advertising. That ingredient-forward, anti-theatre stance found an audience faster than expected, with revenue reportedly climbing from around two million pounds to fifteen million within three years. The pandemic, counterintuitively, was the brand's best stretch, as collapsing online ad costs and quieted travel-retail rivals favored a digitally native challenger.

Momentum drew institutional money. In 2021 a London private-equity firm, making its first move into personal care after bets like Soho House and Rapha, injected ten million pounds to fund US and European expansion, and a Regent Street store followed. The hero categories settled around vitamin C, retinoids, and oversized value-size serums, products engineered to deliver a defined job rather than a lifestyle.

Then the corporate weather turned. The founder stepped back in January 2025, and that summer the company entered a pre-pack administration before a Lancashire retail group acquired the assets in a deal reported near fourteen million pounds, following a rebrand that had disrupted trading. None of that diminishes the formulas, which remain well-regarded for punching above their price, but it reframes the risk: the value-active proposition is intact while the long-term direction under new ownership is still being written.

Sources:[1][2][3]